Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc.
Your view on COEPW
Overview
What the company does, where it operates, and who runs it.
About Coeptis Therapeutics Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Mehalick
- Headquarters
- 105 Bradford Road, Wexford, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Mehalick
- Headquarters
- 105 Bradford Road, Wexford, PA, US
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company dedicated to advancing both innovative cell therapy platforms and a pipeline of generic and branded pharmaceutical products, primarily targeting cancer patients. Its leading oncology assets include CD38-GEAR-NK, a Vy-Gen drug candidate engineered to combat CD38-positive cancers such as multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). Alongside this, the company offers CD38-Diagnostic, an in vitro screening tool designed to identify cancer patients who are most likely to respond favorably to targeted anti-CD38 monoclonal antibody treatments. Beyond its internal pipeline, Coeptis also engages in strategic partnerships. It collaborates with Statera BioPharma on the development and commercialization of STAT-201 for Crohn's disease. Additionally, it holds co-development and ownership rights for CPT60621, a potential therapy for Parkinson's Disease, through a collaboration with Vici Health Sciences, LLC. Established in 2017, the company maintains its headquarters in Wexford, Pennsylvania.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Coeptis Therapeutics Holdings, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Coeptis Therapeutics Holdings, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Coeptis Therapeutics Holdings, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Coeptis Therapeutics Holdings, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Coeptis Therapeutics Holdings, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Coeptis Therapeutics Holdings, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Coeptis Therapeutics Holdings, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Coeptis Therapeutics Holdings, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Coeptis Therapeutics Holdings, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Coeptis Therapeutics Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Coeptis Therapeutics Holdings, Inc.. Press releases and market coverage, newest first.